Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.71 |
| ▸ | ATR | Q13535 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863394 | 0.84 | GRM5 (0.71) | GRM5ATRNPC1RAB9AALDH1A1 | |
| SCHEMBL31060490 | 0.83 | GRM5 (1.00) | GRM5ATRNPC1RAB9A | |
| SCHEMBL3870528 | 0.83 | GRM5 (1.00) | GRM5ATRNPC1RAB9A | |
| SCHEMBL3862527 | 0.81 | GRM5 (0.71) | GRM5ATRNPC1RAB9AALDH1A1 | |
| SCHEMBL3867157 | 0.81 | GRM5 (0.66) | GRM5ATRNPC1RAB9AALDH1A1 | |
| SCHEMBL8283077 | 0.80 | GRM5 (0.78) | GRM5ATRNPC1RAB9A | |
| SCHEMBL3861431 | 0.80 | GRM5 (0.64) | GRM5ATRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3868074 | 0.79 | GRM5 (0.75) | GRM5ATRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3859299 | 0.79 | GRM5 (1.00) | GRM5ATRNPC1RAB9AL3MBTL1 | |
| SCHEMBL3861333 | 0.79 | GRM5 (1.00) | GRM5ATRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1715867-A4 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| EP-1715867-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005079802-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005079802-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GABRA5 | GRM5 1/4885ATR 3153/4885NPC1 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.